Autobahn’s elunetirom Fast Track win puts bipolar depression back in regulatory focus
Bipolar depression needs better options. Autobahn’s elunetirom Fast Track status raises the stakes for its Phase 2 readout.
Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression
Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.